- TODO QUE METAN en la [[Web]] de [[STOP2030]] que [[OMS]] ha designado a [[KEMRI]] como un centro colaborador en la vigilancia de NTDs [https://apps.who.int/whocc/Detail.aspx?XOAHM3sF/C/9r825fA94LA==](https://apps.who.int/whocc/Detail.aspx?XOAHM3sF/C/9r825fA94LA==)
**ESACIPAC (KEMRI) designated as a WHO Collaborating Centre on monitoring and evaluation of NTDs**
The Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), a part of KEMRI, has been designated as a WHO Collaborating Centre on monitoring and evaluation of neglected tropical diseases (NTDs) for the next four years. As part of their commitment, they will carry out activities to support disease mapping and impact assessment surveys for the control and elimination of NTDs.
This newly designated WHO Collaborating Centre will be led by Doris Njomo, PhD, centre director of ESACIPAC, and Collins Okoyo, PhD, a statistician from KEMRI involved in the data collection, modelling and analysis within the STOP2030 consortium.
The STOP2030 consortium congratulates ESACIPAC, and KEMRI, for this important achievement, and celebrates working together in developing our fixed-dose coformulation and making it available where it is most needed.
- El paper de farmacocinética. La clave está en la última frase del abstract: "The results allow the advancement to the next phase of the clinical program to demonstrate efficacy and safety in patients affected by soil-transmitted helminths.". https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329971/
